Sign up USA
Proactive Investors - Run By Investors For Investors

Soleno Therapeutics shares surge on positive patent news

The firm has received a new patent (9,757,384) from the relevant US office, it said in a statement
Soleno Therapeutics shares surge on positive patent news
The firm is developing a Diazoxide Choline Controlled Release Tablet (DCCR), it said

Soleno Therapeutics Inc (NASDAQ:SLNOW) shares added almost 50% in New York as the biopharma group issued positive patent news.

The firm has received a new patent (9,757,384) from the relevant US office, related to the use of certain pharmaceutical formulations to reduce one or more aggressive behaviours in a patient with genetics disorders Prader-Willi syndrome (PWS) or Smith-Magenis syndrome (SMS).

The firm is developing a Diazoxide Choline Controlled Release Tablet (DCCR).

“This patent will further strengthen the intellectual property portfolio for DCCR, our lead product candidate, for the treatment of PWS,” said Anish Bhatnagar, Soleno Therapeutics' chief executive in a statement today.

"Importantly, this most recent patent will provide protection of associated claims into 2035. We expect to leverage additional intellectual property opportunities for DCCR over the coming months.”

Soleno expects to begin a Phase III clinical trial of DCCR in Prader-Willi syndrome (PWS) by the end of 2017.

It is now finalising the design of a randomized, double-blind placebo-controlled study to treat around 100 patients.

This study is expected to take around nine to 12 months to complete. DCCR has orphan drug status for the treatment of PWS in the USA.

View full SLNOW profile View Profile

Related Articles

Paradigm Biopharmaceuticals: Access latest PPT from Proactive's CEO Sessions
May 18 2017
Paul Rennie talked timeline to clinical trial results with investors.
Woman with tissue facing pollen
October 20 2017
Allergy, which saw its market share grow by a percentage point to 13%, is in a strong financial position, with £22.1mln in the bank
mri scanner
July 24 2017
The Assessa PML platform is designed to facilitate the remote transfer, management and storage of MRI scans to help doctors detect progressive multifocal leukoencephalopathy
Copyright © Proactiveinvestors.com, 2017. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use